July 9, 2013

Q1 Productions to Host Global Clinical Risk Management and Regulatory Policy Conference

globalmap.pngThe Global Clinical Risk Management and Regulatory Policy Conference will take place in Alexandria, Virginia on July 11-12, 2013. Throughout the two-day program, executives from industry will have an opportunity to discuss and debate the many challenges associated with profiling the risk of products as well as minimizing these risks and meeting regulatory expectations. With a well-rounded speaking platform that includes not only industry representation but also regulatory bodies, legal perspectives and the healthcare professional, participants will have an unrivaled opportunity to engage, network and learn from leading executives and corporations.

As with all Q1 programs, the focus of the event will not only lie upon the educational content, but also providing attendees with an opportunity to network and build relationships across this highly dynamic and evolving market. For conference sponsors supporting this program, the event will be an ideal vehicle for both learning more about advanced RMPs, but also an opportunity to disseminate information regarding products and services supporting pharmaceutical risk management.

KEY CONFERENCE TAKEAWAYS

  • Harmonizing risk management strategies for global markets

  • Measuring the effectiveness of approved REMS & RMP

  • Working with regulatory agencies to revise risk plans

  • Forecasting the FDA's next steps in determining REMS drug safety improvement

  • Strengthening benefit-risk analysis on an international scale

  • PRESENTATIONS TO INCLUDE

    DEVELOPING A SINGLE, SHARED REMS IN A COLLABORATIVE SETTING
    Brian Malkin, Partner
    FROMMER LAWRENCE & HAUG LLP

    PANEL DISCUSSION: MEASURING THE EFFECTIVENESS OF APPROVED REMS & RMP
    Jeffrey Fetterman, PARAGON RX
    Mostafa Wali, PharmD, SANOFI
    Dessislava Dimitrova, MD, PhD, BRISTOL-MYERS SQUIBB
    Robin Geller, PhD, BAXTER
    Charles Tressler, Pfizer

    FORECASTING THE FDA'S NEXT STEPS IN DETERMINING REMS DRUG SAFETY IMPROVEMENT
    Christopher Milne, DVM, MPH, JD, Director of Research
    TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT

    HARMONIZING RISK MANAGEMENT STRATEGIES FOR GLOBAL MARKETS
    Mostafa Wali, PharmD, Director, Risk Management Officer, Global Pharmacovigilance & Epidemiology
    SANOFI

    And more...

    For more information visit: http://www.q1productions.com/clinicalrisk

    To request information on promotional pricing & registration details please contact:

    Paul Hernandez
    Marketing Director
    Q1 Productions
    312.602.9683
    phernandez@q1productions.com